These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 16192793)

  • 1. Is the activated clotting time dangerous?
    Metz S
    Anesthesiology; 2005 Oct; 103(4):903-4; author reply 904. PubMed ID: 16192793
    [No Abstract]   [Full Text] [Related]  

  • 2. Heparin resistance and antithrombin: should it still be called heparin resistance?
    Levy JH
    J Cardiothorac Vasc Anesth; 2004 Apr; 18(2):129-30. PubMed ID: 15073697
    [No Abstract]   [Full Text] [Related]  

  • 3. Treating heparin resistance with antithrombin or fresh frozen plasma.
    Spiess BD
    Ann Thorac Surg; 2008 Jun; 85(6):2153-60. PubMed ID: 18498854
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Argatroban, bivalirudin, and lepirudin do not decrease clot propagation and strength as effectively as heparin-activated antithrombin in vitro.
    Nielsen VG; Steenwyk BL; Gurley WQ; Pereira SJ; Lell WA; Kirklin JK
    J Heart Lung Transplant; 2006 Jun; 25(6):653-63. PubMed ID: 16730571
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recombinant human antithrombin III restores heparin responsiveness and decreases activation of coagulation in heparin-resistant patients during cardiopulmonary bypass.
    Avidan MS; Levy JH; van Aken H; Feneck RO; Latimer RD; Ott E; Martin E; Birnbaum DE; Bonfiglio LJ; Kajdasz DK; Despotis GJ
    J Thorac Cardiovasc Surg; 2005 Jul; 130(1):107-13. PubMed ID: 15999048
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Review article: heparin sensitivity and resistance: management during cardiopulmonary bypass.
    Finley A; Greenberg C
    Anesth Analg; 2013 Jun; 116(6):1210-22. PubMed ID: 23408671
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relationships between antithrombin activity, anticoagulant efficacy of heparin therapy and perioperative variables in patients undergoing cardiac surgery requiring cardiopulmonary bypass.
    Muedra V; Bonanad S; Gómez M; Villalonga V; Sánchez F; Llopis JE
    Perfusion; 2011 Nov; 26(6):487-95. PubMed ID: 21665912
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Guidelines for monitoring heparin by the activated clotting time when aprotinin is used during cardiopulmonary bypass.
    Hunt BJ; Segal HC; Yacoub M
    J Thorac Cardiovasc Surg; 1992 Jul; 104(1):211-2. PubMed ID: 1377315
    [No Abstract]   [Full Text] [Related]  

  • 9. Case report: a thrombus in the venous reservoir while using bivalirudin in a patient with heparin-induced thrombocytopenia undergoing heart transplantation.
    Wong JK; Tian Y; Shuttleworth P; Caffarelli AD; Reitz BA; Mora-Mangano CT
    Anesth Analg; 2010 Sep; 111(3):609-12. PubMed ID: 20686010
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of activated coagulation time and whole blood heparin measurements with laboratory plasma anti-Xa heparin concentration in patients having cardiac operations.
    Despotis GJ; Summerfield AL; Joist JH; Goodnough LT; Santoro SA; Spitznagel E; Cox JL; Lappas DG
    J Thorac Cardiovasc Surg; 1994 Dec; 108(6):1076-82. PubMed ID: 7983877
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Successful use of Argatroban as a heparin substitute during cardiopulmonary bypass: heparin-induced thrombocytopenia in a high-risk cardiac surgical patient.
    Edwards JT; Hamby JK; Worrall NK
    Ann Thorac Surg; 2003 May; 75(5):1622-4. PubMed ID: 12735590
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical experience with the activated clotting time for the control of heparin and protamine therapy during cardiopulmonary bypass.
    Akl BF; Vargas GM; Neal J; Robillard J; Kelly P
    J Thorac Cardiovasc Surg; 1980 Jan; 79(1):97-102. PubMed ID: 7350393
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Does preoperative level of antithrombin III predict heparin resistance during extracorporeal circulation?
    Rodríguez-López JM; del Barrio E; Lozano FS; Muriel C
    Anesth Analg; 2008 Oct; 107(4):1444-5. PubMed ID: 18806070
    [No Abstract]   [Full Text] [Related]  

  • 14. Recombinant hirudin for extended aortic surgery in patients with heparin-induced thrombocytopenia.
    Bauer M; Koster A; Pasic M; Weng Y; Kuppe H; Hetzer R
    J Thorac Cardiovasc Surg; 1999 Jul; 118(1):191-2. PubMed ID: 10384203
    [No Abstract]   [Full Text] [Related]  

  • 15. [Heparin resistance during cardiopulmonary bypass].
    Maeda R; Fukuda H; Nakaigawa Y; Hiruta M; Hirabayashi Y; Seo N
    Masui; 2003 Sep; 52(9):1003-5. PubMed ID: 14531265
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Heparin resistance during cardiopulmonary bypass. The role of heparin pretreatment.
    Esposito RA; Culliford AT; Colvin SB; Thomas SJ; Lackner H; Spencer FC
    J Thorac Cardiovasc Surg; 1983 Mar; 85(3):346-53. PubMed ID: 6827843
    [No Abstract]   [Full Text] [Related]  

  • 17. Bivalirudin as an adjunctive anticoagulant to heparin in the treatment of heparin resistance during cardiopulmonary bypass-assisted cardiac surgery.
    McNair E; Marcoux JA; Bally C; Gamble J; Thomson D
    Perfusion; 2016 Apr; 31(3):189-99. PubMed ID: 25934498
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A randomized trial of antithrombin concentrate for treatment of heparin resistance.
    Williams MR; D'Ambra AB; Beck JR; Spanier TB; Morales DL; Helman DN; Oz MC
    Ann Thorac Surg; 2000 Sep; 70(3):873-7. PubMed ID: 11016326
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of bivalirudin versus heparin during percutaneous coronary intervention (the Randomized Evaluation of PCI Linking Angiomax to Reduced Clinical Events [REPLACE]-1 trial).
    Lincoff AM; Bittl JA; Kleiman NS; Sarembock IJ; Jackman JD; Mehta S; Tannenbaum MA; Niederman AL; Bachinsky WB; Tift-Mann J; Parker HG; Kereiakes DJ; Harrington RA; Feit F; Maierson ES; Chew DP; Topol EJ;
    Am J Cardiol; 2004 May; 93(9):1092-6. PubMed ID: 15110198
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The impact of heparin concentration and activated clotting time monitoring on blood conservation. A prospective, randomized evaluation in patients undergoing cardiac operation.
    Despotis GJ; Joist JH; Hogue CW; Alsoufiev A; Kater K; Goodnough LT; Santoro SA; Spitznagel E; Rosenblum M; Lappas DG
    J Thorac Cardiovasc Surg; 1995 Jul; 110(1):46-54. PubMed ID: 7609568
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.